{"url_path":"/sec/ewtx/8-k/2026-06-01/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1710072/0001193125-26-249951-index.html","accession_number":"0001193125-26-249951","cik":"0001710072","ticker":"EWTX","issuer_name":"Edgewise Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1710072/0001193125-26-249951-index.html","primary_entity_key":"0001710072","primary_entity_name":"Edgewise Therapeutics, Inc."},"word_count":383,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits\n\n(d) Exhibits:\n\n \n\nExhibit No.\n  \nExhibit Description\n\n99.1\n  \n[Press Release, dated June 1, 2026.](d24037dex991.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\nCautionary Statement Regarding Forward-Looking Statements\n\nThis Current Report on Form 8-K contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this Current Report on Form 8-K that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the Transaction, including the Transaction timeline and potential payments which may become owing to the Company. Words such as “expects,”, “may,” “will,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: uncertainties relating to the timing of the consummation of the Transaction; the possibility that any or all of the conditions to the closing of the Transaction may not be satisfied or waived, including failure to receive required regulatory approvals; the effect of the announcement or pendency of the Transaction on the Company’s ability to maintain relationships with suppliers and other business partners; and risks relating to potential diversion of management attention away from the Company’s ongoing business operations. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that the Company files from time to time with the U.S. Securities and Exchange Commission. These forward-looking statements are made as of the date of this Current Report on Form 8-K, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.\n\nSignatures\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nEDGEWISE THERAPEUTICS, INC.\n\nBy:\n \n\n/s/ Michael Nofi\n\nName:\n \nMichael Nofi\n\nTitle:\n \nChief Financial Officer\n\nDate: June 1, 2026"}